TrialPloS one2014

Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.

Klaus Reither et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.